Sector News

BD plans $540M sale of surgical instrumentation platform to Steris

June 24, 2023
Life sciences

Becton Dickinson, one of the world’s largest medical technology companies, said in a statement Tuesday it has entered into a definitive agreement to sell its surgical instrumentation platform to Steris, an Ohio-based medical device firm specializing in infection prevention.

The sale includes BD’s V. Mueller, Snowden-Pencer and Genesis brands as well as three manufacturing facilities in St. Louis, Cleveland, and Tuttlingen, Germany. Some 360 employees will transfer to Steris when the deal closes by the end of September.

BD’s surgical instrumentation platform is part of the company’s interventional business segment.

In a statement, New Jersey-based BD said selling the platform “advances the ‘Simplify’ pillar” of the firm’s strategy to slim its product portfolio and manufacturing network.

The transaction is significant for Steris, which employs 17,000 people worldwide. The company had global sales of $4.96 billion and a net loss of $27.9 million in its most recent fiscal year.

Needham analysts led by Mike Matson applauded the transaction. READ MORE

By Peter Green


comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach